Addendum
Nivolumab/relatlimab (melanoma) – Addendum to Project A26-65
Report documents
-
Addendum
Nivolumab/relatlimab (melanoma) – Addendum to Project A26-65
Dossier assessment
Indication:
Adults and adolescents 12 years of age and older with advanced (unresectable or metastatic) melanoma with tumour cell programmed cell death ligand 1 expression <1%; first-line treatment
Result of dossier assessment:
- Adults: unchanged after addendum: hint of a minor added benefit
- Adolescents 12 years of age and older: unchanged after addendum: added benefit not proven
Additional information
Federal Joint Committee (GBA)
19-11-2026 A G-BA decision was published.
GBA documents on this decision
Project details
- Project no.
- A26-120
- Commission
- Commission awarded on 06.10.2026 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://doi.org/10.60584/A26-120
Connected Projects
-
Dossier assessment
Nivolumab/relatlimab (melanoma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed